Intelligent Bio Solutions (INBS) Q1 2025 earnings summary

Executive summary

• Revenue increased to $872,287 for the quarter ended September 30, 2024, up from $796,094 year-over-year, driven by customer base expansion, new market entries, and four consecutive quarters of year-over-year growth.

• Gross profit rose to $346,801 from $232,331, with gross margin improving to 39.8% from 29.2% year-over-year.

• Net loss attributable to shareholders increased to $2,685,633 from $2,425,204, primarily due to higher R&D and regulatory expenses.

• Higher-margin, recurring cartridge revenue surpassed reader revenue as the primary driver.

• Completed in-clinic portion of FDA 510(k) clinical study, with submission on track for year-end and US market entry planned for first half of 2025.

Financial highlights

• Revenue grew by $76,193 year-over-year, mainly from increased sales of cartridges and readers.

• Cost of revenue decreased by $38,277, mainly due to lower direct labor and overhead costs.

• Operating expenses totaled $3,198,190, with a significant increase in development and regulatory expenses to $948,752.

• Cash and cash equivalents stood at $3,989,431 as of September 30, 2024.

• Shareholders' equity was $5.95 million at quarter-end.

Outlook and guidance

• Management anticipates continued operating losses and negative cash flows until regulatory approvals and revenue expansion are achieved.

• FDA 510(k) submission planned for Q4 2024, with US market entry targeted for H1 2025.

• Anticipates continued revenue growth as customer base expands and new markets are entered.

• Ongoing R&D and regulatory expenses are expected to increase as the FDA clinical study plan progresses.

• PK study results expected in November to further validate fingerprint sweat as a drug screening method.